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Abstract
Introduction: The objective of this paper was to assess the safety and efficacy of sunitinib malate in patients with well-differentiated 
metastatic pancreatic neuroendocrine neoplasms (PNENs) who relapsed on standard therapy. 
Material and methods: Overall, eight patients with well-differentiated pancreatic neuroendocrine tumours/neoplasm (NET/NEN G1/G2, 
Ki-67 < 20%), who had relapsed on a standard therapy approach, were treated. All had non-resectable, progressive disease. All received 
therapy using a standard dose of sunitinib malate. Adverse events were evaluated using NCI-CTC AE v. 3.0.
Results: Of the eight patients, seven had non-secretor and single secretor tumour (gastrinoma). Partial remission (PR) was noted in three 
patients (one after a single therapeutic line, two after two lines), five patients had stabilisation (SD) — including three individuals after 
three lines, one patient after two lines and another after a single line. Haematological adverse events: leukopenia (25%) — occurred in 
one patient after three lines and in one patient after two lines; anaemia (25%) — in one patient after three lines and in one patient after 
one therapeutic line. Mucocutaneous lesions were noted in 37.5% of patients after 2–3 lines of treatment. All of them experienced fatigue 
syndrome irrespective of the number of therapies. The majority of the patients simultaneously received somatostatin analogues, which 
did not exacerbate the toxicity profile. The median progression-free survival time (PFS) was 11 months.
Conclusions: Sunitinib may be considered as a fairly well-tolerated and effective therapeutic option in progressive non-resectable PNEN patients 
in the second and subsequent lines of treatment, irrespective of the types of treatment previously applied. (Endokrynol Pol 2014; 65 (6): 472–478)
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Streszczenie
Wstęp: Celem pracy była ocena bezpieczeństwa oraz analiza skuteczności jabłczanu sunitynibu u chorych z przerzutowymi wysokozróż-
nicowanymi guzami neuroendokrynnymi trzustki (PNET) w drugiej i kolejnych liniach leczenia. 
Materiał i metody: Analizie poddano 8 pacjentów z wysoko zróżnicowanymi guzami neuroendokrynnymi trzustki (NEN G1/G2, Ki-67 
< 20%), u których wystąpiła progresja choroby i otrzymali sunitynib. Wszyscy chorzy byli w stadium nieoperacyjnym. Sunitynib był 
podawany w standardowej dawce. Działania niepożądane oceniono na podstawie kryteriów NCI-CTC AE v. 3.0. 
Wyniki: Leczono 8 pacjentów; 7 guzów nieaktywnych hormonalnie i 1 o typie gastrinoma. Częściową remisję (PR) uzyskano u 3 chorych (1 po 
1 linii terapeutycznej, 2 — po 2 liniach), 5 chorych miało stabilizację (SD) — w tym 3 było po 3 liniach, 1 po 2 liniach i 1 po 1 linii terapeutycznej. 
Powikłania hematologiczne: leukopenia (25%) — wystąpiły u 1 pacjenta po 3 liniach i u 1 pacjenta po 2 liniach; niedokrwistość (25%) — u 1 
pacjenta po 3 liniach i u 1 pacjenta po 1 linii terapeutycznej. U 37,5% chorych wystąpiły zmiany skórno-śluzówkowe po 2–3 liniach leczenia. U 
100% chorych obserwowano zespół zmęczenia niezależnie od liczby terapii. Większość chorych jednocześnie otrzymywała SSA, co nie pogor-
szyło profilu toksyczności. Mediana czasu wolnego od progresji PFS (progression free survival) – wyniosła 11 miesięcy.
Wnioski: Sunitynib może być rozważany, jako dość dobrze tolerowana, skuteczna opcja terapeutyczna u chorych z nieresekcyjnymi PNET 
w drugiej oraz kolejnych liniach leczenia, niezależnie od rodzaju uprzednio zastosowanych metod.(Endokrynol Pol 2014; 65 (6): 472–478)
Słowa kluczowe: sunitynib; terapia antyangiogenna; SSA; analogi somatostatyny; PRRT; peptydowa terapia radioizotopowa; CTH; chemioterapia
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acceptable toxicity profile and maintenance of quality 
of life at a relatively good level [17].
The aim of this study was to analyse factors influenc-
ing the occurrence, type and severity of adverse events 
based on NCI-CTC AE v. 3.0 (National Cancer Institute 
Common Terminology Criteria for Adverse Events 4.03) 
related to sunitinib applied in subsequent therapeutic 
lines, as well as to analyse the efficiency of this treatment 
in patients with advanced, non-resectable, progres-
sive, well-differentiated pancreatic neuroendocrine 
neoplasms (NETG1/G2), in terms of progression-free 
survival. The assessment encompassed all the patients 
receiving sunitinib therapy in Polish clinics from 2011 
to 2013. 
Material and methods
The analysis encompassed eight patients with histologi-
cally confirmed, well-differentiated PNENs — NENG1 
with proliferation index Ki-67 < 2% and NENG2 with 
2% < Ki-67 < 20%), who were found during or upon 
completion of somatostatin analogue treatment (SSA: 
octerotide acetate — Sandostatin LAR®, lanreotide 
acetate — Somatuline Autogel®) and/or peptide recep-
tor radionuclide therapy (PRRT) and/or chemotherapy 
(CTH) to have experienced progression of the neoplas-
tic disease, and were therefore eligible for sunitinib 
therapy. 
The histopathological diagnoses of these pancreatic 
neuroendocrine tumours took into consideration the 
requirements of the uniform international classification 
of the World Health Organization (WHO) and the Eu-
ropean Neuroendocrine Tumour Society (ENETS) [21, 
22]. Before the treatment, all patients had their serum 
chromogranin A (CgA) concentrations marked, and 
they were later controlled every three months. The state 
of somatostatin receptor expression was evaluated on 
the basis of somatostatin receptor scintigraphy (SRS; 
99mTc-[HYNIC, Tyr3]-octreotide (HYNICTOC) Tektrotyd; 
Polatom, Poland). 
The treatment was administered to patients with 
good performance status evaluated on the WHO scale 
(World Health Organization)/ECOG (Eastern Co-
operative Oncology Group) at 0–1. Prior to the sunitinib 
therapy, concomitant diseases and complications of 
the past oncological treatment were taken into consid-
eration. The performance of the bone marrow and the 
biochemical functions of the following organs were 
evaluated: the kidneys, the liver, the thyroid gland, 
as well as the circulatory system (cardiac ultrasound 
imaging, ECG and blood pressure measurement). Pro-
gression of the disease prior to sunitinib therapy was 
documented in CT and/or MRI.
Introduction
Pancreatic neuroendocrine neoplasms (PNENs) are rare 
neoplasms of the digestive system originating from the 
Diffuse Endocrine System (DES). Most may constitute 
a component of the genetic syndromes of multiple 
endocrine neoplasia (MEN1, MEN2), von Hippel-
Lindau (VHL), or neurofibromatosis type 1 (NF1). [1]. 
PNENs constitute from 2% to 10% of tumours in this 
organ, with an incidence rate of approximately 4–12 per 
1,000,000 individuals. The number of new diagnoses 
has increased in recent years due to more sensitive 
diagnostic methods [2–4]. 
The therapeutic options for non-resectable, ad-
vanced PNEN patients are still unsatisfactory and lim-
ited. In the first line of treatment, it is common to apply 
biological therapies: somatostatin analogues (SSA) are 
recommended in the treatment of slow-growing NETG1 
and NETG2 [5–7]. Chemotherapy is recommended in 
metastatic or locally-advanced, non-resectable NETG2 
and NEC [8–9]. Systemic treatment with streptozotocin 
(STZ) and 5-fluorouracil (5-Fu) and/or adriamycin 
(ADM) gives an objective response rate ranging be-
tween 35 and 40% [10–12], while the combination of 
temozolomide and capecitabine used in the Strosberg 
study provided better results in terms of the objective 
response rate (ORR — 70%) [13]. Radionuclide therapy 
(PRRT) may be used in hormonally active and inactive 
NETG1/G2 tumours as well, but this finding is based 
only on non-randomised analyses [14–16]. 
In 2011, two new oral drugs were approved for 
the treatment of these tumours: the tyrosine multiki-
nase inhibitor sunitinib; and the mammalian target of 
rapamycin kinase everolimus. Thus began a new era 
of targeted treatment for pancreatic neuroendocrine 
tumours [17–19]. 
Pre-clinical trials indicated that PNENs are supplied 
with a dense network of microvessels (hypervascu-
larisation) and manifest high expression of vascular 
endothelial growth factor receptors (VEGFR1, VEGFR2, 
VEGFR3), platelet growth factor receptors (PDGFRα 
and PDGFRβ), stem cell factors (SCF), glial cell line-
derived neurotrophic factors (GDNF) and many other 
signal pathways for neoangiogenesis [20]. Sunitinib 
malate and its active metabolite (SU011248) is an oral 
protein-tyrosine kinase inhibitor with strong antiangio-
genic properties [17, 18]. This justifies the application 
of sunitinib in PNENs in particular NETG1 and NETG2 
groups of patients. The drug has demonstrated a sig-
nificant clinical improvement in terms of progression-
free survival (PFS) in a double-blind, randomised trial 
compared to a placebo (median PFS 11.4 months vs. 5.5 
months, HR 0.42; 95% CI: 0.26–0.66; P < 0.001), with an 
474
PR
A
C
E 
O
RY
G
IN
A
LN
E
Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours  Ewa Wachuła et al.
Sunitinib was administered at a dose of 37.5 mg 
a day every day. The therapy was continued until 
progression or unacceptable toxicity occurred. The 
administration of sunitinib was halted when adverse 
events beyond grade 3 were noted based on NCI CTC 
AE v. 3.0 [23]. Continuation of the therapy was possible 
upon the improvement of the clinical condition below 
the 2nd degree. The drug dose was reduced by 12.5 mg 
in the event of prolonged adverse events related to 
sunitinib. The safety of the therapy was assessed based 
on the analysis of complications reported by the patients 
or examined in the laboratory. 
The efficiency of the therapy was determined on the 
basis of radiological examination according to the criteria 
of the Response Evaluation Criteria In Solid Tumours 
(RECIST) version 1.0. Examinations to assess the response 
to CT or MRI treatment were performed every 12 weeks. 
An examination was performed to verify the corre-
lation between the number and type of the individual 
therapeutic lines used before sunitinib therapy, and the 
sunitinib tolerance and the influence on the therapeutic 
benefit (the percentage of obtained responses and the 
progression-free survival time). 
Results
The assessment encompassed eight patients receiving 
sunitinib therapy. The group comprised five women 
(62.5%) mean age 44 years (range 33 to 60) and three 
men (37.5%) mean age 47.2 years (range 29 to 67). The 
average age at the onset of the disease was 42.1 years 
(range: 26–63), while the age at the onset of the suni-
tinib therapy was 48.8 years (range: 29–67). All patients 
had PS WHO/ECOG of 0 except for two patients with 
WHO/ECOG of 1. 
Three patients were diagnosed with NEN G1, and 
five with NEN G2. Among them, there were seven 
patients with hormonally inactive tumours and one 
with a gastrinoma tumour without concomitant MEN1 
syndrome (MEN1, multiple endocrine neoplasia). 
A 29-year-old man was found to have a pathogenic 
R167W mutation (c.499C > T) in one allele of the VHL 
gene, which had clinical implications in the form of von 
Hippel-Lindau syndrome. Mean CgA in those patients 
was 115.56 ng/mL (range 2 to 442.4) (Table I).
All the patients underwent surgery on either 
a radical or a palliative basis. Three patients received 
radical surgery with removal of the primary pancreatic 
tumour (the R0 procedure), two patients underwent 
a cytoreduction procedure (the R1/R2 procedure), while 
the remaining three were administered exploratory 
laparotomy with collection of specimen for histopatho-
logical examination. Secondary cytoreduction was per-
formed in three individuals (metastasectomy — surgical 
removal of metastases) in the liver, with one patient 
undergoing the procedure twice (Table II). 
Sunitinib malate was used in the second and subse-
quent therapeutic lines for metastatic NEN tumours of 
the pancreas. During sunitinib therapy, SSA treatment 
— activated in the first line of treatment (87.5%) — was 
continued. One patient showed no expression of soma-
tostatin receptors. Five patients (62.5%), before being 
put on sunitinib, received peptide receptor radionuclide 
therapy (PRRT), including one individual receiving 
such a therapy twice, with an interval of two years. 
Half of the patients (50%) had previously undergone 
chemotherapy (with five different schemes: cisplatin 
with etoposide, 5-fluorouracil with adriamycin, gem-
citabine), including one individual undergoing two 
systemic treatment lines (Table III).
Assessment of therapeutic response
Partial remission (PR) was obtained in three patients. 
In the remaining patients, the response was assessed 
as stabilisation of the disease (SD) — including three 
Table I. Characteristics of patients and pancreatic tumour 
before sunitinib therapy
Tabela I. Charakterystyka pacjentów i cech guzów trzustki 
przed terapią sunitynibem
Parameter Result
Female/male 5/3
Mean age at initial diagnosis (years/range) 42.1 (29–67)
Mean age at sunitinib therapy (years/range) 48.9 (29–67)
NETG1/NETG2 (%) 3/5 (37/63%)
CgA (mean/range) 115.56 ng/mL (2–442)
Table II. Characteristics of clinical parameters of a pancreatic 
tumour and metastatic lesions before sunitinib therapy
Tabela II. Charakterystyka parametrów klinicznych guza 
trzustki oraz zmian przerzutowych przed terapią sunitynibem
Parameters Results
Radical /non-radical/tumour sampling surgery (%) 3/2/3 (37.5/25/37.5)
Localisation of the primary 
tumour in the pancreas (%)
Head 2 (25%)
Body 4 (50%)
Tail 4 (50%)
Initial size of the tumour, T feature (mm/range) 81.5 (40–120)
Pre-sunitinib size of the tumour (mm/range) 45.3 (0–124)
Location of metastatic lesionsLiver mts (%) 7 (87.5)
Lymph node mts (%) 4 (50%)
Local recurrence of pancreatic tumour (%) 5 (62.5)
Secondary cytoreduction (metastasectomy* (%) 3 (37.5%)
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patients with three lines of past treatment, one after 
two lines and one after one therapeutic line (Table IV). 
Assessment of survival times
The longest period of sunitinib treatment was 39 months 
(from three cycles in a dose reduced to 25 mg due 
to third-degree dermatological complications). The 
patient had previously received two lines of treatment: 
somatostatin analogues and PRRT. The patient contin-
ues her sunitinib therapy. The median progression-
free survival time including all patients (PFS) was 
11.5 months. 
Assessment of safety of sunitinib therapy  
depending on the number and type of past  
therapeutic lines
Most adverse effects related to sunitinib therapy were 
mild or moderate (degree of severity 1st or 2nd degree 
according to NCI CTC AE). Severe adverse events (in 
the 3rd and 4th degrees) referred to haematological com-
plications: leukopenia (25%) — in one patient after three 
therapeutic lines, and in one patient after two lines; 
anaemia (25%) — in one patient after three lines, and in 
one patient after one therapeutic line. Mucocutaneous 
lesions were observed in three (37.5%) patients after 
2–3 lines of treatment. Patients with haematological 
complications in the 3rd or 4th degree received prior 
chemotherapy.
The treatment was terminated in two patients — in 
one after ten months of therapy, due to bleeding from 
the pancreatic head tumour (prior to sunitinib, he re-
ceived only one line — SSA). The other patient, after 
Table III. Number and type of therapeutic lines before starting 
sunitinib therapy
Tabela III. Liczba i rodzaj linii terapeutycznych przed 
włączeniem sunitynibu
Number of therapy lines 
before sunitinib therapy
Type of sytemic therapy 
before sunitinib treatment 
Number  
of patients
Single SSA 2
Two Chemotherapy 2
PRRT + SSA 1
Three SSA 2
Chemotherapy (two lines  
of systemic therapy)
PRRT
Four SSA 1
Chemotherapy
PRRT (twice)
SSA — somatostatin analogues therapy; PRRT — peptide receptor radionuclide 
therapy
Table IV. Type and severity of sunitinib adverse effects in the individual patients assessed according to the criteria of NCI 
CTC AE v. 3.0
Tabela IV. Rodzaj i stopień nasilenia działań niepożądanych sunitynibu u poszczególnych pacjentów ocenianych według 
kryteriów CTC AE v. 3.0
Type and severity of toxicity 
(Degree 1–4)
P-1 P-2 P-3 P-4 P-5 P-6 P-7 P-8
Mucocutaneous 3 1 3 2 2 0 1 1
Hand-foot syndrome 3 0 2 0 1 0 1 1
Fatigue syndrome 2 2 1 2 2 1 1 1
Haematological:
a) Leukopenia
b) Anaemia
c) Thrombocytopenia
a) 0
b) 0
c) 0
a) 4
b) 2
c) 1
a) 0
b) 0
c) 0
a) 0
b)4
c) 0
a) 0
b) 0
c) 2
a) 0
b) 3
c) 0
a) 4
b) 2
c) 1
a) 0
b) 0
c) 1
Dyspeptic symptoms (abdominal 
pains)
1 2 0 2 0 0 2 0
Nephrological 0 0 2 1 0 0 0 0
Cardiological 0 1 1 1 0 0 0 1
Tumour bleeding 0 0 0 4 0 0 0 0
Endocrinological (hypothyroidism) 0 0 2 0 0 0 0 2
Diarrhoea 1 2 2 2 2 1 1 1
Vomiting 0 0 0 2 0 0 0 0
Nausea 1 1 1 1 1 0 0 0
Constipation 1 0 0 0 0 0 0 0
Infection 2 3 1 2 1 0 0 0
0 — no symptoms; 1 — mild symptoms; 2 — moderate symptoms; 3 — serious complications ; 4 — life-threatening symptoms
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12 months of sunitinib therapy, experienced immunity 
disorders complicated by severe pneumonia (he had 
previously received three therapeutic lines: SSA, PRRT 
and CTH with cisplatin). 
All eight patients (100%) reported suffering from 
fatigue syndrome and diarrhoea (1st or 2nd degree) ir-
respective of the therapeutic lines administered prior 
to the sunitinib therapy. Half of the patients (50%) on 
sunitinib had previously been diagnosed and treated 
for arterial hypertension (concomitant disease). All 
of these patients were receiving anti-hypertensive 
therapy that required modification due to clinically 
significant incidents of increased arterial pressure. No 
patients manifested arterial hypertension as a new 
symptom induced by the tyrosine kinase inhibitor 
therapy.
Dermatological complications occurred in seven 
individuals (87.5%) in the form of mucosal damage, 
with two individuals experiencing 3rd degree effects. 
Five individuals suffered skin damage on their hands 
and feet in the form of palmar-plantar erythrodysesthe-
sia, including one patient with 3rd degree effects. This 
patient had undergone four therapeutic lines before 
receiving sunitinib therapy (SSA, CTH and two courses 
of PRRT) (Figs. 1A, B).
Two patients were diagnosed with iatrogenic hypo-
thyroidism that required hormonal supplementation 
(in one individual after two therapeutic lines — SSA 
and PRRT, in the other — after one line with SSA). The 
majority of the patients (87.5%), during their sunitinib 
therapies, received SSA, which had no influence on the 
exacerbation of the toxicity profile (Tables V and VI).
Discussion
Data concerning the effects of antiangiogenic therapy 
based on patient profiles, and on the number and type 
of therapies administered prior to sunitinib, is very 
limited and mainly derived from analysis of a few 
randomised clinical trials [17, 18].
There are ongoing efforts to determine the optimal 
therapeutic sequence for patients with pancreatic 
neuroendocrine neoplasms/tumours. The introduction 
of new molecular agents into clinical practice has sig-
nificantly influenced the progress in PNENs treatment, 
both in terms of symptom control and antiproliferation 
effects [17–19].
This paper analyses the factors influencing the 
occurrence and severity of complications related to 
sunitinib malate — a multikinase inhibitor — applied 
in the second and subsequent therapeutic lines in pa-
tients with metastatic NETG1/G2. None of the patients 
received sunitinib in the first line of treatment. In all of 
the patients, irrespective of the number of previously 
administered therapeutic options, one could observe 
adverse events of varying severity, but primarily of low 
degree (1st and 2nd degree of NCI-CTC AE). 
The greatest clinical benefits were observed in those 
patients who had undergone only somatostatin ana-
logue therapy before sunitinib treatment (regardless 
of the type: ‘cold’ — SSA, or ‘hot’ analogues — PRRT). 
Efficacy and safety of sunitinib did not appear to be 
affected by such features as: the differentiation degree 
of the G1 and G2 tumour cells, the size of the original 
mass of the pancreatic tumour, the elevated CgA con-
Figures 1A, B. Dermatological complications in the form of hand-foot syndrome (palmar-plantar erythrodysesthesia) — 3rd degree of 
CTC AE
Rycina 1A, B. Powikłania dermatologiczne w postaci zespołu ręka-stopa (erytrodyzestezja dłoniowo-podeszwowa) — 3 stopnia CTC AE
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centration before activating the sunitinib therapy, the 
expression of somatostatin receptors, the secretional 
status of the tumour, or the number of therapeutic lines 
applied before sunitinib as opposed to the quality of the 
therapeutic lines (SSA, PRRT, chemotherapy).
Haematological complications (mainly neutropenia) 
were strictly related to the past chemotherapy treat-
ment and increased the risk of infections during the 
sunitinib treatment (62.5%). The other toxicities due to 
this therapy were related to individual characteristics 
of the patients (e.g. a concomitant disease or clinical 
implications of the von Hippel-Lindau syndrome) as 
well as with the tumour parameters (e.g. infiltration of 
vessels and nerve plexuses, location of the tumour in 
the head of the pancreas). Simultaneous administra-
tion of SSA with tyrosine multikinase inhibitor did 
not affect the exacerbation of the treatment tolerance, 
its effects or the deterioration in quality of life [17, 24]. 
This observation is important from the clinical point of 
view, particularly in the light of the recent findings of 
the CLARINET study that confirm the antiproliferation 
action of lanreotide in PNENs [6].
Table IV. Dependency between the number of therapeutic lines before sunitinib, the therapeutic response, and the duration of 
the response
Tabela IV. Zależność między liczbą linii terapeutycznych przed sunitynibem, odpowiedzią na leczenie i czasem trwania 
odpowiedzi
 P-1 P-2 P-3 P-4 P-5 P-6 P-7 P-8
Number of therapeutic lines before sunitinib 4 3 2 1 2 3 2 1
The best therapeutic response [RECIST]* SD SD SD SD PR SD PR PR
PFS or duration of the response (months) 12 11 39 10 14 9 14 7
Severe adverse events [4] CTC AE] Leukopenia Anaemia Leukopenia
P-1 to P-8 — consecutive patients; *RECIST — Response Evaluation Criteria in Solid Tumour
Table V. Summary of sunitinib adverse effects depending on the severity assessed on the basis of the criteria of CTC AE v. 3.0
Tabela V. Zestawienie działań niepożądanych sunitynibu w zależności od stopnia nasilenia ocenianego na podstawie kryteriów 
CTC AE v. 3.0
Type and severity of toxicity 
(Degree 1–4)
No symptoms  
No. (%)
Degree 1 
No. (%)
Degree 2 
 No. (%)
Degree 3 
No. (%)
Degree 4  
No. (%)
Haematological complications:
 a) Leukopenia
 b) Anaemia
 c) Thrombocytopenia
a) 6 (75)
b) 4 (50)
c) 4 (50)
a) 0
b) 0
c) 3 (37.5)
a) 0
b) 2 (25)
c) 1 (12.5)
a) 0
b) 1 (12.5)
c) 0
a) 2 (25)
b) 1 (12.5)
c) 0
Non-haematological complications related to sunitinib:
Mucocutaneous 1 (12.5) 3 (37.5) 2 (25) 2 (25) 0
Hand-foot syndrome 3 (37.5) 3 (37.5) 1 (12.5) 1 (12.5) 0
Fatigue syndrome 0 4 (50) 4 (50) 0 0
Nephrological 6 (75) 1 (12.5) 1 (12.5) 0 0 
Cardiological, including arterial hypertension 4 (50) 4 (50) 0  0 0 
Tumour bleeding 7 (87.5) 0 0 0 1 (12.5)
Endocrynological, including hypothyroidism 6 (75) 0 2 (25) 0 0
Infections 3 (37.5) 2 (25) 2 (25) 1 (12.5) 0
Gastroenterological symptoms related to sunitinib: 
Abdominal pain 4 (50) 1 (12.5) 3 (37.5) 0 0
Diarrhoea 0 4 (50) 4 (50) 0 0
Vomiting 7 (87.5) 0 1 (12.5) 0 0 
Nausea 3 (37.5) 5 (62.5) 0 0 0
Constipation 7 (87.5) 1 (12.5) 0 0 0
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In the first clinical analyses concerning sunitinib 
safety in PNENs, published in 2008, the therapy en-
compassed 109 patients, with 107 of them receiving 
sunitinib (including: carcinoids — 38.3%, and pancre-
atic tumours — 61.6%). Sunitinib was administered in 
the dose of 50 mg/day in a pattern of six weeks (four 
weeks of therapy with two weeks of interval). Among 
the PNENs patients, objective response rate (ORR) was 
achieved in 16.7% of the patients, stabilisation of the 
disease in 68%; slightly worse results were achieved 
in the group of carcinoids in terms of response, while 
comparable in terms of the median progression free 
survival time (7.7 months vs. 10.2 months). Over 80% of 
the patients in both groups survived for one year. 88.8% 
manifested fatigue syndrome induced during the treat-
ment with the tyrosine kinase inhibitor, including over 
27% in the 3rd degree of NCI CTC AE [18, 20]. Similar 
effects were indicated in the study by Raymond et al. 
[17], where sunitinib therapy with a dose of 37.5 mg 
daily encompassed 171 patients, obtaining the PFS rate 
of 11.4 months vs. 5.5 months in the placebo group [HR 
0.42; 95% CI, 0.26–0.66; P < 0.001], which is confirmed 
in our small group of patients with the same PFS 11.5 
months. Treatment efficiency in the form of objective 
response rate was obtained in 9.3% (95% CI, 3.2–15.4), 
but failed to be obtained in the placebo group. The most 
common adverse events related to the drug included: 
diarrhoea (59%), nausea (45%), vomiting (34%), malaise 
(34%), fatigue syndrome (32%), neutropenia (29%), 
abdominal pain (28%), arterial hypertension (26%), 
palmar-plantar erythrodysesthesia (23%), cachexia 
(22%), mucosal damage (22%), bleeding (20%), throm-
bocytopenia (17%) and others, similar to the findings 
of the Raymond study [17].
Conclusions
Sunitinib malate proved to be a fairly well tolerated 
and effective therapeutic option in patients with well-
differentiated NETG1 and NETG2 neuroendocrine pan-
creatic tumours, when used in the 2nd and subsequent 
lines of treatment, irrespective of the number of previ-
ously administered pharmacological or radioisotope 
treatments. Further studies are needed to determine 
the optimal safe sequence of treatment methods.
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